Feature Image

Medical Marijuana, Inc. CEO Interviewed in Forbes Article on the DEA and CBD

Dr. Titus, CEO of Medical Marijuana, Inc., quoted in online Forbes piece covering controversial new move by the DEA.

Last Wednesday, news broke that the DEA had included an update in the Federal Register establishing a new drug code specifically for marijuana extracts. Some media outlets jumped on the story immediately, falsely reporting that the move by the DEA had essentially ended the CBD hemp oil industry, making it illegal.

While much of the industry panicked, Medical Marijuana, Inc. surveyed the landscape before releasing a statement affirming CBD hemp oil’s legality. In the week since, more accurate reporting has been done on the issue, with Medical Marijuana, Inc. leading the way in clarifying what the DEA’s action means for the industry.

Medical Marijuana, Inc.’s CEO Dr. Stuart Titus was interviewed as part of a story on Forbes delving into the DEA’s entry in the Federal Register. In the piece by Debra Borchardt, Dr. Titus discuss a crucial 2014 court case in which the Hemp Industries Association (HIA) won an important case decision against the DEA. The court ruled that hemp was not illegal to import and sell domestically.

CBD hemp oil products

Dr. Titus clarified the legality of CBD hemp oil products saying, “The ninth circuit court of appeals has conclusively held that hemp products such as those marketed by the company [Medical Marijuana] which are derived from the part of the cannabis plant, which is exempt from the controlled substances act, is legal for import from Europe.”

Also part of the article was Russ Baer, a spokesperson for the DEA who interviewed to clarify the purpose of the change. Baer said, “The FRN published earlier this week did not have anything to do with re-scheduling CBD or anything at all to do with hemp.”

According to the Forbes article, the DEA stated it created the new internal drug code for marijuana extracts, including CBD, as a means to more easily and accurately track scientific research on cannabis.

“Creating an internal record-keeping system allows us to distinguish the extracts from other parts of the cannabis plant and ultimately makes our work more efficient,” said Baer.

That means that this move may be, in conjunction with the DEA’s new easement on the restrictions for cannabis research, a way to prepare for what it sees as a potential increase in new studies, not as a means to outlaw CBD hemp oil.

To keep up to date with changes in the hemp and marijuana industries, follow our news feed.

hempmeds-blog-image-what-is-cannabidiol-10-13-16-ver2
  • December 22, 2016
  • Jeffrey Stamberger